Molecular diagnostics company OncoCyte (NYSE:OCX) announced that two investors have agreed to purchase nearly $8 million of its common stock in a registered offering. Pura Vida Investments and another institutional investor combined for the $7.6 million offering, which was completed directly with the investors and included no placement agent fees. OncoCyte is slated to sell […]